Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O'Connor, M. J., & Bakkenist, C. J. (2015). The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget.

Vendetti, Frank P., Alan Lau, Sandra Schamus, Thomas P. Conrads, Mark J. O'Connor, and Christopher J. Bakkenist. "The Orally Active and Bioavailable ATR Kinase Inhibitor AZD6738 Potentiates the Anti-tumor Effects of Cisplatin to Resolve ATM-deficient Non-small Cell Lung Cancer in Vivo." Oncotarget 2015.

Vendetti, Frank P., et al. "The Orally Active and Bioavailable ATR Kinase Inhibitor AZD6738 Potentiates the Anti-tumor Effects of Cisplatin to Resolve ATM-deficient Non-small Cell Lung Cancer in Vivo." Oncotarget 2015.